Aliases & Classifications for Agoraphobia

MalaCards integrated aliases for Agoraphobia:

Name: Agoraphobia 12 52 42 14 69
Fear of Open Spaces 12

Classifications:



External Ids:

Disease Ontology 12 DOID:593
ICD10 33 F40.0 F40.00
MeSH 42 D000379
NCIt 47 C34362
UMLS 69 C0001818

Summaries for Agoraphobia

Disease Ontology : 12 A phobic disorder involving the specific anxiety about being in a place or situation where escape is difficult or embarrassing or where help may be unavailable.

MalaCards based summary : Agoraphobia, also known as fear of open spaces, is related to personality disorder and schizophrenia. An important gene associated with Agoraphobia is HTR1A (5-Hydroxytryptamine Receptor 1A), and among its related pathways/superpathways are Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways and Serotonergic synapse. The drugs Clonazepam and Paroxetine have been mentioned in the context of this disorder. Affiliated tissues include brain, thyroid and cortex, and related phenotypes are behavior/neurological and cardiovascular system

Wikipedia : 72 Agoraphobia is an anxiety disorder characterized by symptoms of anxiety in situations where the person... more...

Related Diseases for Agoraphobia

Diseases related to Agoraphobia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 79)
id Related Disease Score Top Affiliating Genes
1 personality disorder 29.9 HTR1A MAOA SLC6A2 SLC6A4
2 schizophrenia 28.3 HTR1A MAOA SLC6A2 SLC6A4
3 panic disorder 11.6
4 anxiety disorder 11.2
5 conjunctival degeneration 10.6 HTR1A SLC6A4
6 anodontia 10.6 HTR1A SLC6A4
7 pompholyx 10.6 HTR1A SLC6A4
8 anosognosia 10.6 HTR1A SLC6A4
9 conjunctival pigmentation 10.6 MAOA SLC6A4
10 luxation of globe 10.6 HTR1A SLC6A4
11 ornithosis 10.5 MAOA SLC6A4
12 pyromania 10.5 MAOA SLC6A4
13 tongue disease 10.5 MAOA SLC6A4
14 primary angle-closure glaucoma 10.5 HTR1A SLC6A4
15 intrahepatic gall duct cancer 10.5 MAOA SLC6A4
16 pauci-immune glomerulonephritis with anca 10.5 MAOA SLC6A4
17 mandibular cancer 10.5 HTR1A SLC6A4
18 laryngeal adductor paralysis 10.3 HTR1A SLC6A4
19 tinea pedis 10.3 HTR1A MAOA SLC6A4
20 dissociative disorder 10.3 PIR SLC6A4
21 renpenning syndrome 10.3 HTR1A MAOA SLC6A4
22 paranoid personality disorder 10.3 HTR1A PIR
23 chronic dacryoadenitis 10.3 HTR1A MAOA SLC6A4
24 obsessive-compulsive personality disorder 10.3 HTR1A MAOA SLC6A4
25 acquired aneurysmal subarachnoid hemorrhage 10.3 HTR1A MAOA SLC6A4
26 hypoglycemic coma 10.3 HTR1A MAOA SLC6A4
27 autoimmune-related retinopathy and optic neuropathy 10.3 GRPR HTR1A SLC6A4
28 cecal benign neoplasm 10.3 HTR1A MAOA SLC6A4
29 bladder hepatoid adenocarcinoma 10.3 SLC6A2 SLC6A4
30 vallecula cancer 10.3 HTR1A MAOA SLC6A4
31 aicardi-goutieres syndrome 2 10.3 HTR1A MAOA SLC6A4
32 albinism, oculocutaneous, type v 10.3 HTR1A MAOA SLC6A4
33 social phobia 10.2
34 atrial fibrillation, familial, 10 10.2 HTR1A MAOA SLC6A4
35 carotid stenosis 10.2 MAOA SLC6A4
36 colon mucinous adenocarcinoma 10.2 MAOA SLC6A4
37 hemorrhagic cystitis 10.1 MAOA SLC6A2 SLC6A4
38 generalized anxiety disorder 10.1
39 obsessive-compulsive disorder 10.1
40 parkinson disease, late-onset 10.0 HTR1A MAOA SLC6A4
41 neurogenic bladder 10.0 MAOA PIR SLC6A4
42 suppurative periapical periodontitis 10.0 OPRK1 SLC6A4
43 chagas disease 9.9 MAOA SLC6A4
44 acute female pelvic peritonitis 9.9 OPRK1 SLC6A4
45 eating disorder 9.9
46 separation anxiety disorder 9.8
47 thyroiditis 9.8
48 keratosis 9.8 HTR1A MAOA SLC6A2 SLC6A4
49 partial motor epilepsy 9.8 HTR1A MAOA SLC6A2 SLC6A4
50 craniosynostosis, adelaide type 9.8 HTR1A MAOA SLC6A2 SLC6A4

Graphical network of the top 20 diseases related to Agoraphobia:



Diseases related to Agoraphobia

Symptoms & Phenotypes for Agoraphobia

MGI Mouse Phenotypes related to Agoraphobia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.86 CCKBR GRPR HTR1A MAOA OPRK1 RGS2
2 cardiovascular system MP:0005385 9.76 HTR1A MAOA PTK7 RGS2 SLC6A2 SLC6A4
3 homeostasis/metabolism MP:0005376 9.56 CCKBR GRPR HTR1A MAOA OPRK1 SLC6A2
4 nervous system MP:0003631 9.28 CCKBR HTR1A MAOA OPRK1 PTK7 RGS2

Drugs & Therapeutics for Agoraphobia

Drugs for Agoraphobia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 49)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
2
Paroxetine Approved, Investigational Phase 4,Phase 3 61869-08-7 43815
3
Sertraline Approved Phase 4 79617-96-2 68617
4
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
5
Alprazolam Approved, Illicit, Investigational Phase 4,Phase 1 28981-97-7 2118
6 Anticonvulsants Phase 4
7 Antidepressive Agents Phase 4,Phase 3
8 Antidepressive Agents, Second-Generation Phase 4,Phase 3
9 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 3
10 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3
11 GABA Agents Phase 4,Phase 1
12 GABA Modulators Phase 4,Phase 1
13 Neurotransmitter Agents Phase 4,Phase 3,Phase 1
14 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3
15 Psychotropic Drugs Phase 4,Phase 3,Phase 1
16
Serotonin Phase 4,Phase 3 50-67-9 5202
17 Serotonin Agents Phase 4,Phase 3
18 Serotonin Uptake Inhibitors Phase 4,Phase 3
19 Central Nervous System Stimulants Phase 4
20 Dopamine Agents Phase 4
21 Dopamine Uptake Inhibitors Phase 4
22 Lisdexamfetamine Dimesylate Phase 4
23 Anti-Anxiety Agents Phase 4,Phase 1
24 Central Nervous System Depressants Phase 4,Phase 1
25 Hypnotics and Sedatives Phase 4,Phase 1
26 Tranquilizing Agents Phase 4,Phase 1
27
Cycloserine Approved Phase 2 68-41-7 401 6234
28 Anti-Bacterial Agents Phase 2
29 Antibiotics, Antitubercular Phase 2
30 Anti-Infective Agents Phase 2
31 Antimetabolites Phase 2
32 Antitubercular Agents Phase 2
33 Renal Agents Phase 2
34
Citalopram Approved 59729-33-8 2771
35
Adenosine Approved, Investigational 58-61-7 60961
36
Magnesium Sulfate Approved, Vet_approved 7487-88-9 24083
37
Caffeine Approved, Nutraceutical 58-08-2 2519
38 Antiparkinson Agents
39 Autonomic Agents
40 Cholinergic Agents
41 Cholinergic Antagonists
42 Muscarinic Antagonists
43 Parasympatholytics
44 Peripheral Nervous System Agents
45 Analgesics
46 Anti-Arrhythmia Agents
47 Phosphodiesterase Inhibitors
48 Purinergic P1 Receptor Antagonists
49 Vasodilator Agents

Interventional clinical trials:

(show top 50) (show all 58)

id Name Status NCT ID Phase Drugs
1 Long Term Treatment of Panic Disorder With Clonazepam or Paroxetine Completed NCT02852577 Phase 4 Clonazepam;Paroxetine
2 A Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder Completed NCT00677352 Phase 4 sertraline;Paroxetine
3 Paroxetine vs Placebo Combined With Aerobic Exercise or Relaxation in Panic Disorder Completed NCT00540098 Phase 4 paroxetine + aerobic exercise;Paroxetine + relaxation;Placebo + aerobic exercise;Placebo + relaxation
4 Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity Completed NCT01863459 Phase 4 Lisdexamfetamine Dimesylate;placebo
5 Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders Active, not recruiting NCT00182533 Phase 4 Sertraline;Placebo
6 A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks Terminated NCT00634790 Phase 4 alprazolam XR
7 Mechanisms of Panic Disorders Treatment Unknown status NCT01323556 Phase 2, Phase 3
8 Virtual Reality Exposure Therapy in Agoraphobic Participants Completed NCT00734370 Phase 2, Phase 3
9 Treatment of Panic Disorder: Long Term Strategies Completed NCT00000368 Phase 3 Paroxetine or other medication - algorithm used
10 Comparison of Psychotherapy Programs to Treat Panic Disorder Completed NCT00353470 Phase 3
11 Internet-Versus Group-Administered Cognitive Behavior Therapy for Panic Disorder Completed NCT00845260 Phase 3
12 Treatment of Social Phobia and Panic Disorder in Adults Completed NCT00619138 Phase 3
13 Effects of Prismatic Spectacle Lenses on Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria Completed NCT00785135 Phase 3
14 Augmentation of Psychotherapy With D-Cycloserine in Agoraphobia Completed NCT01928823 Phase 2 D-Cycloserine
15 Effectiveness of Intensive Cognitive Behavioral Therapy in Treating Adolescent Panic Disorder and Agoraphobia Completed NCT00576719 Phase 2
16 Physical Exercise Versus Cognitive-behavioral Therapy (CBT) for Panic Disorders: A Randomised Controlled Trial Completed NCT01076777 Phase 2
17 Exposure Therapy for Fear of Falling in Older Adults Completed NCT01609322 Phase 2
18 Effectiveness of Cognitive Behavioral Therapy With Panic Control Treatment for Adolescents With Panic Disorder Completed NCT00705380 Phase 2
19 Cognitive Behavior Therapy vs Exposure in Vivo in the Treatment of Panic Disorder With Agoraphobia Recruiting NCT01680237 Phase 2
20 Improve: Integrating Emotion Focused Components Into Psychological Therapy Recruiting NCT02822443 Phase 2
21 The Modular Protocol for Mental Health (MPMH) Enrolling by invitation NCT03143634 Phase 1, Phase 2
22 An Bioequivalence Study Of Xanax Extended Release Tablets From Two Different Manufacturing Sites Completed NCT01330472 Phase 1 Xanax XR tablets 3 mg (sourced from Caugus);Xanax XR tablets 3 mg (sourced from Barceloneta)
23 Study of Virtual Reality Therapy and Cognitive Behavior Therapy in Panic Disorder With Agoraphobia Unknown status NCT00129610
24 Virtual Reality and Concept of Control in the Treatment of Acrophobia Unknown status NCT02020824
25 Thought Field Therapy and Cognitive Therapy for Agoraphobia Completed NCT00932919
26 Longterm Outcome of Inpatient Cognitive and Behavioral Therapies for Agoraphobia Completed NCT01446172
27 Physical Activity and Cognitive Behavioural Therapy in Panic Disorder and Agoraphobia Completed NCT01928810
28 Cognitive Behavioral Therapy in Panic Disorder Completed NCT00772746
29 Internet-based Exposure Therapy for Panic Disorder Completed NCT03061448
30 Physical Activity and Cognitive Behavioural Therapy in Panic Disorder Completed NCT01788800
31 Vestibular Dysfunction In Adult Patients With Panic Disorder With or Without Agoraphobia Completed NCT00004367
32 Can Thought Field Therapy (TFT) be Helpful for Patients With an Anxiety Disorder? Completed NCT00202709
33 Pilot Study of Vestibular Rehabilitation Training for Panic Disorder With Vestibular Dysfunction Completed NCT00004366
34 Cognitive Behavior Psychotherapy in Panic Disorder Completed NCT01025908
35 Interpretation Modification Program for Social Phobia Completed NCT00684541
36 Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months Completed NCT00711737
37 Assessment of the Prevalence of Major Psychiatric Disorders in a Cohort of Women With Clinical Criteria Corresponding to Pure, Abortive-form, Obstetrical, Antiphospholipid Syndrome Completed NCT02833194
38 Genetic Causes of Panic Disorder Completed NCT00083265
39 Youth Mayo Clinic Anxiety Coach Pilot Study Completed NCT02205177
40 Validity of a Self-administered Questionnaire to Screen Phobia of Falling in the Elderly Completed NCT02387047
41 Clinical Trial of Transdiagnostic Cognitive-Behavior Therapy for Anxiety Disorders Recruiting NCT02811458
42 Providing Tools for Effective Care and Treatment of Anxiety Disorders Recruiting NCT02605668
43 Effectiveness of a Transdiagnostic Internet-based Treatment for Emotional Disorders Recruiting NCT02345668 Treatment as Usual (Pharmacological Treatment)
44 Efficacy of a Transdiagnostic Internet-based Protocol in Community Sample Recruiting NCT02578758
45 Examining the Effects of Reduced Environmental Stimulation on Anxiety Recruiting NCT03051074
46 Building an Outcomes Assessment Infrastructure to Assess Anxiety Treatment Recruiting NCT02305537
47 Effect of Mindfulness Meditation on Physiological Response to Unpredictable Stimuli Recruiting NCT03206437
48 Dimensional Brain Behavior Predictors of CBT Outcomes in Pediatric Anxiety Recruiting NCT02810171
49 Expectation of Unpleasant Events in Anxiety Disorders Recruiting NCT00055224
50 The Unified Protocol for the Treatment of Emotional Disorders in Spanish Public Mental Health System Recruiting NCT03064477

Search NIH Clinical Center for Agoraphobia

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: agoraphobia

Genetic Tests for Agoraphobia

Anatomical Context for Agoraphobia

MalaCards organs/tissues related to Agoraphobia:

39
Brain, Thyroid, Cortex, Pituitary, Amygdala, Breast, Cingulate Cortex

Publications for Agoraphobia

Articles related to Agoraphobia:

(show top 50) (show all 551)
id Title Authors Year
1
No Effects of D-Cycloserine Enhancement in Exposure With Response Prevention Therapy in Panic Disorder With Agoraphobia: A Double-Blind, Randomized Controlled Trial. ( 28820746 )
2017
2
Support Vector Machine Analysis of Functional Magnetic Resonance Imaging of Interoception Does Not Reliably Predict Individual Outcomes of Cognitive Behavioral Therapy in Panic Disorder with Agoraphobia. ( 28649205 )
2017
3
Burden and Distress in Caregivers of Patients With Panic Disorder and Agoraphobia. ( 27861457 )
2017
4
Transdiagnostic group CBT vs. standard group CBT for depression, social anxiety disorder and agoraphobia/panic disorder: Study protocol for a pragmatic, multicenter non-inferiority randomized controlled trial. ( 28114915 )
2017
5
Reduction in Costs after Treating Comorbid Panic Disorder with Agoraphobia and Generalized Anxiety Disorder. ( 28418834 )
2017
6
Thought Field Therapy Compared to Cognitive Behavioral Therapy and Wait-List for Agoraphobia: A Randomized, Controlled Study with a 12-Month Follow-up. ( 28676782 )
2017
7
Psychoticism in patients with panic disorder with or without comorbid agoraphobia. ( 28345374 )
2017
8
Comorbidity and Suicidality in Patients Diagnosed with Panic Disorder/Agoraphobia and Major Depression. ( 28636577 )
2017
9
Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study. ( 28845177 )
2017
10
Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis. ( 27071857 )
2016
11
A Comparison of Psychoanalytic Therapy and Cognitive Behavioral Therapy for Anxiety (Panic/Agoraphobia) and Personality Disorders (APD Study): Presentation of the RCT Study Design. ( 27594602 )
2016
12
SECOND-STAGE TREATMENTS FOR RELATIVE NONRESPONDERS TO COGNITIVE BEHAVIORAL THERAPY (CBT) FOR PANIC DISORDER WITH OR WITHOUT AGORAPHOBIA-CONTINUED CBT VERSUS SSRI: A RANDOMIZED CONTROLLED TRIAL. ( 26663632 )
2016
13
Predictors of Dropout From Cognitive-Behavioral Group Treatment for Panic Disorder With Agoraphobia: An Exploratory Study. ( 27385412 )
2016
14
Panic disorder with agoraphobia from a behavioral neuroscience perspective: Applying the research principles formulated by the Research Domain Criteria (RDoC) initiative. ( 26877119 )
2016
15
Sustained Resolution of Panic Disorder, Agoraphobia, and Generalized Anxiety Disorder With a Single Ketamine Infusion: A Case Report. ( 27828703 )
2016
16
Threat expectancy bias and treatment outcome in patients with panic disorder and agoraphobia. ( 27061246 )
2016
17
Agency and Anxiety: Delusions of Control and Loss of Control in Schizophrenia and Agoraphobia. ( 27725796 )
2016
18
Agoraphobia Related to Unassertiveness in Panic Disorder. ( 26915016 )
2016
19
Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults. ( 27730622 )
2016
20
The Mobility Inventory for Agoraphobia Avoidance Alone Scale: Factor Structure and Psychometric Properties of Subscales. ( 27449053 )
2016
21
Facing the fear - clinical and neural effects of cognitive behavioural and pharmacotherapy in panic disorder with agoraphobia. ( 26837851 )
2016
22
Cognitive Models for Panic Disorder With Agoraphobia: A Study of Disaggregated Within-Person Effects. ( 27123977 )
2016
23
Agoraphobia With and Without Panic Disorder: A 20-Year Follow-up of Integrated Exposure and Psychodynamic Therapy. ( 26588081 )
2016
24
A discussion of various aspects of panic disorder depending on presence or absence of agoraphobia. ( 27423353 )
2016
25
Insomnia Symptoms Following Treatment for Comorbid Panic Disorder With Agoraphobia and Generalized Anxiety Disorder. ( 27019339 )
2016
26
Platzschwindel, agoraphobia and their influence on theories of anxiety at the end of the nineteenth century: theories of the role of biology and 'representations' (Vorstellungen). ( 27450798 )
2016
27
The role of treatment delivery factors in exposure-based cognitive behavioral therapy for panic disorder with agoraphobia. ( 27235836 )
2016
28
Treating Treatment-Resistant Patients with Panic Disorder and Agoraphobia Using Psychotherapy: A Randomized Controlled Switching Trial. ( 25722042 )
2015
29
Predictors of short- and long-term avoidance in completers of inpatient group interventions for agoraphobia. ( 25917291 )
2015
30
Agoraphobia and Melancholia: Thoughts on Milrod's "Emptiness in Agoraphobia Patients". ( 26263925 )
2015
31
Association of human microRNAs miR-22 and miR-491 polymorphisms with panic disorder with or without agoraphobia in a Korean population. ( 26361067 )
2015
32
Ghrelin and lipid levels in panic disorder before and after treatment and their relationship with agoraphobia. ( 26400133 )
2015
33
Predictors of the application of exposure in vivo in the treatment of agoraphobia in an outpatient clinic: An exploratory approach. ( 26308791 )
2015
34
Evidence for chronic low-grade systemic inflammation in individuals with agoraphobia from a population-based prospective study. ( 25875094 )
2015
35
Panic disorder and agoraphobia: A direct comparison of their multivariate comorbidity patterns. ( 26480214 )
2015
36
Frontal cortex absolute beta power measurement in Panic Disorder with Agoraphobia patients. ( 26093831 )
2015
37
Metabolic decoupling in daily life in patients with panic disorder and agoraphobia. ( 26028550 )
2015
38
The combined use of virtual reality exposure in the treatment of agoraphobia. ( 26150057 )
2015
39
Social Anxiety Disorder and Agoraphobia in Dermatology Patients; Two Cases and a Review of the Literature. ( 25721467 )
2015
40
A systematic review of predictors and moderators of improvement in cognitive-behavioral therapy for panic disorder and agoraphobia. ( 26443228 )
2015
41
CLINICAL CONSEQUENCES OF THE REVISED DSM-5 DEFINITION OF AGORAPHOBIA IN TREATMENT-SEEKING ANXIOUS YOUTH. ( 25845579 )
2015
42
Intensive behavioral therapy for agoraphobia. ( 25479049 )
2015
43
An admixture analysis of age of onset in agoraphobia. ( 25898330 )
2015
44
Panic disorder and agoraphobia: an overview and commentary on DSM-5 changes. ( 24865357 )
2014
45
Two-year course of generalized anxiety disorder, social anxiety disorder, and panic disorder with agoraphobia in a sample of latino adults. ( 24731232 )
2014
46
Analysis of gastrin-releasing peptide gene and gastrin-releasing peptide receptor gene in patients with agoraphobia. ( 24912045 )
2014
47
Cognitive and Guided Mastery Therapies for Panic Disorder with Agoraphobia: 18-Year Long-Term Outcome and Predictors of Long-Term Change. ( 25452222 )
2014
48
The relationships among separation anxiety disorder, adult attachment style and agoraphobia in patients with panic disorder. ( 25218272 )
2014
49
Therapist effects and the outcome-alliance correlation in cognitive behavioral therapy for panic disorder with agoraphobia. ( 24275067 )
2014
50
Altered top-down and bottom-up processing of fear conditioning in panic disorder with agoraphobia. ( 23611156 )
2014

Variations for Agoraphobia

Expression for Agoraphobia

Search GEO for disease gene expression data for Agoraphobia.

Pathways for Agoraphobia

GO Terms for Agoraphobia

Cellular components related to Agoraphobia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.86 CCKBR GRPR HTR1A OPRK1 PTK7 RGS2
2 membrane GO:0016020 9.85 CCKBR GRPR HTR1A MAOA OPRK1 PTK7
3 integral component of plasma membrane GO:0005887 9.5 CCKBR GRPR HTR1A OPRK1 PTK7 SLC6A2
4 neuron projection GO:0043005 9.02 OPRK1 RGS2 SLC6A2 SLC6A4 STMN1

Biological processes related to Agoraphobia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.88 CCKBR GRPR HTR1A OPRK1 PTK7 STMN1
2 social behavior GO:0035176 9.46 GRPR SLC6A4
3 neurotransmitter transport GO:0006836 9.43 SLC6A2 SLC6A4
4 vasoconstriction GO:0042310 9.37 HTR1A SLC6A4
5 sensory perception GO:0007600 9.32 CCKBR OPRK1
6 behavior GO:0007610 9.26 HTR1A OPRK1
7 monoamine transport GO:0015844 9.16 SLC6A2 SLC6A4
8 phospholipase C-activating G-protein coupled receptor signaling pathway GO:0007200 9.13 CCKBR GRPR OPRK1
9 dopamine uptake involved in synaptic transmission GO:0051583 8.62 SLC6A2 SLC6A4

Molecular functions related to Agoraphobia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 beta-tubulin binding GO:0048487 9.16 RGS2 SLC6A2
2 monoamine transmembrane transporter activity GO:0008504 8.96 SLC6A2 SLC6A4
3 dopamine:sodium symporter activity GO:0005330 8.62 SLC6A2 SLC6A4

Sources for Agoraphobia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....